<DOC>
	<DOC>NCT00324077</DOC>
	<brief_summary>The purpose of this study is to find out whether adding a new drug, dasatinib, to imatinib is safe, and whether the combination of the two drugs will help decrease the number of cells that contain the Philadelphia chromosome.</brief_summary>
	<brief_title>Phase I Study of Dasatinib (BMS-354825) and Imatinib in Subjects With Chronic Myeloid Leukemia in Chronic Phase</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Myeloid</mesh_term>
	<mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia, Myeloid, Chronic-Phase</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>males and females, 18 or older chronic phase Ph+ or BCRABL positive CML current complete hematologic response to imatinib lack of major molecular response on imatinib for at least one year on the same imatinib dose for at least 6 months adequate hepatic and renal function History of accelerated or blast phase CML Serious uncontrolled medical disorder or active infection Significant cardiovascular disease or bleeding disorder Concurrent use of medications at risk of causing Torsades de Pointe</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Chronic phase chronic myelogenous leukemia (CML)</keyword>
</DOC>